Amitiza Hits Mark In Confirmatory Opioid-Induced Bowel Dysfunction Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Sucampo/Takeda’s constipation treatment Amitiza meets primary endpoint in Phase III study of OBD, with a clean safety profile. Sucampo now sets its sights on a supplemental NDA for a third indication.